Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

Novo Nordisk rose as much as 4% after England's drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major cardiovascular events in people living with overweight or obesity. The new recommendation the National Institute for Health and Care Excellence (NICE), England's drug price regulator, will significantly expand access to Wegovy on the country's National Heal ...

Healthcare - The UK's NICE has recommended Novo Nordisk's Wegovy (2.4mg) for reducing the risk of major cardiovascular events in adults with cardiovascular disease and obesity, marking a significant milestone for GLP-1 medications in cardiovascular prevention [2][9] - The final guidance for the treatment is expected by the end of April 2026, with plans for integration into existing NHS cardiovascular care pathways, potentially broadening the market for weight-loss drugs [3][9] Trade - The U.S. government is launching a digital refund portal for $166 billion in duties collected under the Trump administration's tariffs, following a Supreme Court ruling that deemed these tariffs unlawful [4][9] - The Treasury is adopting a "Digital Only" payment model via the ACE portal to manage the volume of claims, emphasizing the need for businesses to ensure their ACH setup is active [5] Energy & Tech - Microsoft and Engine No. 1 are in discussions for a $7 billion natural gas-fired power project in Texas, aimed at providing dedicated electricity for a large-scale data center campus [6][9] - Chevron has clarified that no commercial terms have been finalized for its participation in the project, which reflects a trend of tech companies securing energy resources for AI workloads [7] Asia-Pacific - Australia's S&P/ASX 200 index rose 1.6% to 8,618.20, supported by government signals of assistance for the private sector, including potential payment deferrals and loan restructuring [8][9] - The Australian government signed a Memorandum of Understanding with Anthropic to collaborate on AI safety and economic data tracking, marking the first arrangement under the National AI Plan [10] Commodities & Crypto - Gold prices have maintained a three-day gain amid shifting geopolitical tensions, with President Trump's comments suggesting a potential end to hostilities with Iran, leading to a drop in crude oil prices [11] - CoinShares is set to begin trading on the Nasdaq following a SPAC merger, valuing the crypto manager at approximately $1.2 billion and enhancing its presence in the U.S. market [12]

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Wegovy presentation is displayed in New Columbia, Pennsylvania, U.S., November 13, 2023. REUTERS/Hannah Beier/Illustration/File Photo Purchase Licensing Rights, opens new tab April 1 (Reuters) - UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's (NOVOb.CO), opens new tabWegovy to reduce the risk of serious h ...

Core Insights - Eli Lilly and Novo Nordisk are leveraging artificial intelligence (AI) to transform drug development processes, significantly impacting the speed at which new medicines are delivered to patients [1][4]. Eli Lilly - Eli Lilly has entered a $2.75 billion partnership with Insilico Medicine, gaining exclusive rights to develop drugs using Insilico's Pharma.ai platform, which has already produced 28 drug candidates, with nearly half in clinical testing [3][7]. - The company has implemented AI technologies in its manufacturing processes, including digital twin technology and computer vision, to enhance production efficiency and quality control [5]. - Eli Lilly's revenue from GLP-1 drugs has seen substantial growth, with Mounjaro sales doubling to $23 billion and Zepbound revenue increasing from $4.9 billion to $13.5 billion, contributing to over half of the company's total revenue of $65 billion [6]. Novo Nordisk - Novo Nordisk has generated nearly $100 billion in cumulative sales from its drugs Ozempic and Wegovy, focusing on reducing clinical trial durations through AI agents trained on internal and competitor data [12]. - The AI agents are actively used in clinical trials to identify protocol gaps and manage data, which has reduced reliance on external contractors for analytical tasks [13]. - Novo Nordisk has partnered with Nvidia to utilize the Gefion sovereign AI supercomputer for large-scale drug discovery, emphasizing the financial impact of reducing time-to-market for new drugs [14]. - The company has been selective in rolling out AI tools, learning from experiences where costs outweighed benefits, indicating a strategic approach to AI implementation [15]. Industry Implications - The integration of AI across various stages of drug development, from discovery to manufacturing and clinical execution, is creating a competitive advantage that traditional productivity enhancements cannot achieve [16].

[music] We're back on Morning Trade Live. Let's focus on Novo Nordisk, the company announcing a new drug subscription [music] plan today. More on that in a second with Marley.But the chart has been nothing short of a disaster. The stock is trading near four-year lows and is [music] down more than 75% from its all-time high in late June of 2024. Look at that.So, that's the focus of the morning trade. Joining us now for a closer look, as we promised, is Marley. Good morning, Marley.just walk us through the de ...

The company is trying to win customers by offering a "lower, predictable monthly price†for its obesity drugs. ...

Group 1 - Novo Nordisk announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) [4] - The subscription program is available on telehealth platforms, including LifeMD and Hims & Hers [4] - Cash-paying patients can choose from 3-, 6-, or 12-month subscription options [4]